Table 2.
Outcomes | Standard-dose anticoagulation (n = 5) | Therapeutic-dose anticoagulation (n = 5) | Tissue plasminogen activator (n = 5) |
---|---|---|---|
Primary outcome | |||
Median of percent change of P./F ratio within 48 h of enrollmenta (Q1, Q3)b | −15.8 (−28.0–24.1) | −7.6 (−14.5–68.9) | 7.1 (−19.5–8.4) |
Other outcomes | |||
In-hospital mortality (%) | 4 (80) | 2 (40) | 5 (100) |
Median difference of the SOFA score within 48 h of enrollmentc (Q1, Q3) | 1 (0–1) | 0 (−1–0) | 1 (0–2) |
ICU discharge (%) | 1 (20) | 3 (60) | 0 (0) |
ICU stays (d) | 11 (8–12) | 8 (4–19) | 7 (6–10) |
Hospital stays (d) | 11 (8–16) | 16 (8–20) | 7 (6–10) |
Cerebrovascular accident (%) | 0 | 0 | 0 |
Major bleedingd (%) | 0 | 0 | 0 |
Severe thrombocytopeniae (%) | 0 (0) | 1 (20.0) | 0 (0) |
(Q1, Q3), interquartile range 25% - 75%.
P/F ratio, Partial pressure of arterial oxygen (PaO2) to the fraction of inspired oxygen (FiO2) ratio. This index is a clinical indicator of hypoxemia and acute respiratory distress syndrome severity (ARDS severity: mild 200–300, moderate 100–200, and severe <100).
The sequential organ failure assessment score (SOFA) is used to assess organ function status in patients admitted to the intensive care unit (ICU) according to 6 components: the respiratory, cardiovascular, hepatic, coagulation, renal, and neurological systems.
Major bleeding according to the International Society of Thrombosis and Haemostasis classification in nonsurgical patients.
Severe thrombocytopenia, defined as a platelet count <20,000 (cell/μL).